(HealthDay News) — The US Department of Health and Human Services (HHS) and US Food and Drug Administration (FDA) recently announced a plan to remove all petroleum-based synthetic dyes from the nation ...

The DOJ has sent letters to CHEST and other journals asking that editors answer questions about bias and misinformation.

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

The combination of toripalimab, nimotuzumab, and chemotherapy showed “promising antitumor activity with acceptable toxicity,” researchers wrote.

This move is the latest in a series of attempts by the Trump administration to eliminate DEI/DEIA programs and reduce NIH funding.

CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

Progress has been made in reducing overall cancer mortality, largely driven by sustained declines in lung cancer,” the researchers wrote.

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

Pediatric cancer patients and their caregivers largely prefer to access test results immediately through the patient portal rather than wait to hear about results from oncologists, according to survey ...

Until prospective data are available, researchers recommend that patients with ER-low breast cancer “should be counseled regarding the potential benefit” of adjuvant endocrine therapy.

Cancer apps can provide patients with helpful tools, but there are risks associated with these apps, according to experts.

The Trump administration is weighing a plan to cut nearly a third of the federal health budget, according to a memo obtained by CNN.